OS Therapies (OSTX) executive compensation, 2025 proxy

Paul A. Romness, MPH, President and Chief Executive Officer, was paid $3.4M in 2024, up 854% from $360,000 the year before.

Open OSTX in Gloom →
OS Therapies' chart, financials and news, free in your browser.Open OSTX in Gloom →
Filed
August 25, 2025
Annual meeting
October 14, 2025
Pay year
2024
Named executives
3
CEO total pay
$3.4M+854% vs prior year
CEO option award
$2,754,3162024 grant-date fair value
CEO incentive bonus
$200,000Related to two financing transactions
CEO salary
$480,0002024 annual base salary
Petit total compensation
$665,0462024 total
Acevedo total compensation
$158,5232024 total
Petit option award
$245,0462024 grant-date fair value

How MPH was paid

$3.4M in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary14%Bonus6%Option awards80%

Named executive officers

ExecutiveTotal
Paul A. Romness, MPHPresident and Chief Executive Officer$3,434,316
Robert G. Petit, Ph.D.Chief Medical and Scientific Officer$665,046
Christopher AcevedoChief Financial Officer$158,523

What changed and why

  • $3.4M$3,434,316 was CEO total compensation in 2024, including a $2,754,316 option award.
  • $200K$200,000 was a one-time CEO incentive bonus tied to two 2024 financing transactions.
  • $480K$480,000 was the CEO’s 2024 salary, versus $360,000 in 2023.
  • $665K$665,046 was Chief Medical and Scientific Officer Robert Petit’s total 2024 compensation.
  • $159K$158,523 was Chief Financial Officer Christopher Acevedo’s total 2024 compensation.
  • 50%Executives were eligible for performance bonuses of up to 50% of base salary, subject to board approval.

Other OS Therapies proxy statements

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.